Vicki L. Goodman - 05 Dec 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Reporting relationship: Chief Medical Officer
Issuer ticker: MURA
Reported as of: 05 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2025, 08:45:53 UTC
Prior SEC filing: 10 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Vicki L. Goodman

Key filing fact

Vicki L. Goodman filed Form 4 for Mural Oncology plc (MURA) on 05 Dec 2025.

Key facts

This page summarizes Vicki L. Goodman's Form 4 filing for Mural Oncology plc (MURA).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Dec 2025, 08:45.

Change

Previous filing in this sequence was filed on 10 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001901477 Primary reporting owner

Goodman Vicki L

Relationship: Chief Medical Officer
Address: C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
Signature: /s/ Vicki L. Goodman
Signature date: 05 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MURA transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -84,727
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -135,604
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 135,604
Exercise price: $3.61
Footnotes: F3

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -65,000
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 65,000
Exercise price: $3.43
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Vicki L. Goodman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").

Footnote F2

Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.

Footnote F3

Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.